Pfizer Reports Positive Top-Line Results From Phase III Pain Study of ALO-02

Pfizer has reported positive top-line results from a Phase III open-label long-term safety study of ALO-02, oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules, in patients with moderate-to-severe chronic, non-cancer pain.
Pharmaceutical Business Review